Sign in with Google. Opens in new tab
bullish
SpringWorks Therapeutics (SWTX): A Compelling Biotech Buyout Thesis with Limited Downside
SUMMARY
- SpringWorks Therapeutics represents a highly attractive risk-reward opportunity with substantial upside potential from an imminent acquisition.
- The company is currently in play with confirmed acquisition talks and multiple signs pointing to a transaction at a significant premium to current levels.
- Current price: $50, Target price: $70-85, representing approximately 50% upside with limited downside risk.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Nikkei 225 Index Rebalance: Rohm (6963) To Replace NTT Data Group (9613)
- Krungthai Card (KTC TB): Buying Opportunity After Margin Call
- StubWorld: Melco (200 HK) Needs To Fall
- Lotte Corp Sells 145 Billion Won Worth of Treasury Shares to Lotte Moolsan - Negative Governance
- EB Event Trade Setup: HD KSOE Lining up a New Deal with HD Hyundai Heavy as the Underlying
Top Unpaywalled Insights
More »- "The Data Bottleneck in Quant Finance — and How to Break It" With David Forino, CTO of Quanted
- The New OS for Quant Finance: OpenBB, AI Agents & the Death of Legacy Terminals | New Barbarians ...
- Curator's Cut: Building Materials Moves, Benchmarking Gold Miners & Semaglutide in India and Japan
- [IO Technicals 2025/25] Bearish Momentum Strengthens
- VEON (VEON US): Launches Third Phase of Share Buyback Program After Share Pullback
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- SpringWorks Therapeutics (SWTX): A Compelling Biotech Buyout Thesis with Limited Downside18 Mar 2025
x